AbbVie Inc.
Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.
AbbVie (ABBV) raised its dividend 5.5% to $1.73 despite a 36% drop in Humira sales. Skyrizi and Rinvoq offset losses, but Skyrizi faces patent expiry in 2033. The company generated $17.8B in free cash flow, covering dividends. ABBV's $10.9B Apogee acquisition adds leverage but management aims to reduce it within three years.
Solstice Advanced Materials, AbbVie, and Oracle are identified as potentially undervalued stocks. Solstice trades at $61.37 with a 38.7% discount to fair value, expecting 22% annual earnings growth. AbbVie trades at $260.21 with a 42.5% discount, forecasting 23.4% growth. Oracle trades at $154.04 with a 29.8% discount, anticipating 24.7% revenue growth.
AbbVie's (ABBV) cancer drug Etentamig showed a 74% response rate in a pivotal trial, outperforming standard treatments by 28.3 percentage points. The Phase 3 study met its progression-free-survival target in relapsed or refractory multiple myeloma patients. Regulatory review and safety data are pending.
Over the past 7 days, alphai's AI scored 13 news stories mentioning ABBV (AbbVie Inc.). Coverage has skewed bullish: 5 bullish, 6 neutral, and 2 bearish.
Recent ABBV coverage spans financial news, technology and corporate actions.
In the last 30 days, ABBV insiders filed 1 SEC Form 4 transaction — no purchases and 1 sale ($8.2M). The most active reporter was Donoghoe Nicholas, EVP, CHIEF BUS/STRAT OFFICER, with 1 filing.
Dividend raise may attract income investors, but sharp Humira sales decline and added leverage could pressure the stock.
Trial result already public; article offers no new data.
Strong trial data could boost AbbVie's stock and oncology pipeline valuation.
Apogee Therapeutics (APGE), now a subsidiary of AbbVie, has deregistered unsold securities worth up to $300M following its merger with Andor Merger Co. The merger, completed on September 3, 2026, terminated all offerings under the registration statement.
Apogee Therapeutics (APGE) director Lisa Bollinger cashed out vested stock options in a merger deal with AbbVie. The options, covering 48,780 shares, were canceled and exchanged for $135.11 per share minus exercise prices ranging from $41.66 to $85.00. The transaction occurred on September 3, 2026, under a merger agreement dated June 18, 2026.
alphai scores every news story that mentions ABBV with an AI model for sentiment and relevance, and aggregates insider trades from AbbVie Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
AbbVie (ABBV) raised its dividend 5.5% to $1.73 despite a 36% drop in Humira sales. Skyrizi and Rinvoq offset losses, but Skyrizi faces patent expiry in 2033. The company generated $17.8B in free cash flow, covering dividends. ABBV's $10.9B Apogee acquisition adds leverage but management aims to reduce it within three years.
3 min readSolstice Advanced Materials, AbbVie, and Oracle are identified as potentially undervalued stocks. Solstice trades at $61.37 with a 38.7% discount to fair value, expecting 22% annual earnings growth. AbbVie trades at $260.21 with a 42.5% discount, forecasting 23.4% growth. Oracle trades at $154.04 with a 29.8% discount, anticipating 24.7% revenue growth.
2 min readAbbVie's (ABBV) cancer drug Etentamig showed a 74% response rate in a pivotal trial, outperforming standard treatments by 28.3 percentage points. The Phase 3 study met its progression-free-survival target in relapsed or refractory multiple myeloma patients. Regulatory review and safety data are pending.
2 min readApogee Therapeutics (APGE), now a subsidiary of AbbVie, has deregistered unsold securities worth up to $300M following its merger with Andor Merger Co. The merger, completed on September 3, 2026, terminated all offerings under the registration statement.
1 min readApogee Therapeutics (APGE) director Lisa Bollinger cashed out vested stock options in a merger deal with AbbVie. The options, covering 48,780 shares, were canceled and exchanged for $135.11 per share minus exercise prices ranging from $41.66 to $85.00. The transaction occurred on September 3, 2026, under a merger agreement dated June 18, 2026.
1 min readJ&J shares rose 1% to $277.955. AbbVie's experimental myeloma drug showed 74% response rate, 60% risk reduction. J&J's Carvykti drove 6.8% operational growth in Q2. Reuters notes AbbVie's drug complements, not replaces, J&J's treatment. J&J's stock is 44.08% above GF Value estimate.
2 min readAbbVie (ABBV) completed its $10.9 billion acquisition of Apogee Therapeutics (APGE), paying $135.11 per share. The deal strengthens AbbVie's immunology pipeline, including Apogee's lead asset, zumilokibart, for atopic dermatitis. AbbVie expects the acquisition to be dilutive to earnings until 2032. AbbVie reaffirmed its 2026 EPS guidance of $13.87-$14.07, including a $0.14 per-share dilutive impact. ABBV closed at $261.72, up 0.67%.
2 min readAbbVie (ABBV) reported positive Phase 3 trial results for etentamig, showing a 74% objective response rate and 60% risk reduction in disease progression in relapsed/refractory multiple myeloma patients. The study met primary endpoints of ORR and PFS, with manageable safety profile. Full results will be presented at the 23rd International Myeloma Society Annual Meeting in 2026.
3 min readTanya Dorff and Oliver Sartor discuss ABBV-969, an antibody-drug conjugate targeting PSMA and STEAP1 for prostate cancer. Phase 1 data showed 67% PSA50 response and 45% objective response in 29 patients with measurable disease, with a median duration of 11 months. The drug is being explored for phase 3 trials, with dosing optimization ongoing.
2 min readU.S. President Trump has secured drug-pricing deals with over 20 pharmaceutical companies, including Pfizer, Johnson & Johnson, and Novo Nordisk, to reduce prescription costs. Agreements involve 'most-favoured-nation' pricing, sales through TrumpRx.gov, and U.S. investment pledges in exchange for tariff relief. Companies like Pfizer and Novo Nordisk have committed to significant price reductions on specific drugs.
3 min read
